Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Ramsay (ASX:RHC) share price down on FY24 earnings update

The Ramsay Health Care Ltd (ASX:RHC) share price down 2% after giving an update about items affecting its FY24 result.

The Ramsay Health Care Ltd (ASX: RHC) share price down 2% after giving an update about FY24.

Ramsay Health Care is a large private hospital operator in Australia and Europe.

FY24 earnings update

The ASX healthcare share revealed it’s expecting its 2024 financial year net profit after tax (NPAT) to be in the range of between $884 million to $889 million. This will include the after-tax cash profit on the sale of Ramsay Sime Darby (a Malaysian private hospital unit).

Ramsay revealed its FY24 net profit after tax and minority interests from continuing operations is expected to be between $265 million to $270 million, compared to $278.2 million in FY23.

The company announced a number of negative items.

Negative items to report

It’s expecting to include non-cash impairments and accelerated write-downs against the book value of underperforming assets in both Ramsay Sante (mainland Europe operations) and the UK region of $24.5 million after tax and minority interests. This is not helpful for the Ramsay share price.

Another item is $13.1 million after tax and minority interests relating to a reduction in value of ‘interest rate swaps‘ in Ramsay Sante’s debt facilities.

As result of the expected impairment charges and writedowns, Ramsay’s FY24 depreciation, amortisation and impairment charge is expected to be $1.13 billion, above the top end of its range of between $1 billion to $1.1 billion.

Non-recurring items in total, including those mentioned above, are expected to make a negative contribution to the result of approximately $29.5 million after tax and minority interests.

Excluding the impact of non-recurring items, the FY24 net profit after tax and minority interests from continuing operations is expected to be in the range of $294 million to $299 million.

Final thoughts on the Ramsay share price

The private health insurer said its underlying result has been driven by “improving activity trends and labour productivity, combined with a focus on sustainable performance acceleration programs and improved tariff indexation.”

There’s also a fight between private hospitals and private health insurers which could impact Ramsay’s profitabilty, depending on how things go.

It’s not one I’m looking to add to my own portfolio because of the strained dynamic of funding, though there is a tailwind of ageing demographics.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content